NO-platform
NO platform allows you to synthesize original hybrid molecules consisting of pharmaceutically active compounds (API), prostaglandins (PG) and nitric oxide donors (NO-donors)
Main News
* Gurus successfully completed preclinical trials of asthma treatment drug * Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma

Portfolio

Innovative drugs

Innovative drugs
Respiratory system
GUR-501 Asthma treatment First in class

GUR-501 has a potential to be first drug with new mode of action. Asthma causes acute bronchospasm. ~5% of population suffer from asthma. Funded: $721,000. Supported by

Stage: Preclinical trials
Innovative drugs
Genito-urinary system
GUR-001 Erectile dysfunction treatment (ED)

Unique drug candidate that is expected to have a sufficient advantage vs MUSE suppository: higher efficiency and no pain effect. Unlike Caverject, injections are not needed. 25% of men aged 40-70  have moderate ED, and 10% of men have severe ED

Stage: Discovery research
Innovative drugs
Cardiovascular system
GUR-201 Critical Limb Ischemia treatment (CLI) Best-in-class

GUR-201 is designed to treat CLI caused by diabetes or peripheral artery disease. CLI leads to severe complications up to amputation. 1%-2% of population suffer CLI

Stage: Preclinical trials
Innovative drugs
Respiratory system
GUR-502 COPD treatment (Chronic Obstructive Pulmonary Disease)

COPD is a lung disease characterized by progressive and irreversible airway obstruction and frequent coughing. Main causes are tobacco smoking and air pollution. COPD has no cure yet.  3%-10% of population are suffering from COPD

Stage: Discovery research
Innovative drugs
Nervous system
GUR-802 Parkinson’s disease treatment

In PD a person's brain slowly stops producing a neurotransmitter called dopamine. A person gradually loses the ability to regulate their movements. No cure exist for PD. PD begins at 0.5% of the population aged 60. Medication costs $2500 per year

Stage: Discovery research

Highly Effective cosmetics

Highly Effective cosmetics
Anti-aging line
REG-201 Anti-aging skin recovery Fast Launch

This innovative complex allows to restore moisture and elasticity of the skin by restoring the power of the capillary network, which decreases with age

Stage: Safety study
Highly Effective cosmetics
Hair growth stimulation
REG-103 Hair growth stimulator В продаже

This innovative molecular complex acts on hair follicles stimulating hair growth on a head by increasing blood supply to follicles

Stage: In sales
Highly Effective cosmetics
After cosmetic surgery
REG-301 Skin recovery after cosmetic surgery Fast Launch

REG-301 is innovative molecular complex, which is expected to allows  recovering damages after cosmetic surgery several times  faster . These damages comprises scars, hematomas, etc..

Stage: Safety study

Innovative drugs

Respiratory system

Discovery research Preclinical trials Clinical trials
P-IP-II
90%

GUR-501 Asthma treatment

75%

GUR-502 COPD treatment (Chronic Obstructive Pulmonary Disease)

Nervous system

Discovery research Preclinical trials Clinical trials
P-IP-II
80%

GUR-802 Parkinson’s disease treatment

Genito-urinary system

Discovery research Preclinical trials Clinical trials
P-IP-II
80%

GUR-001 Erectile dysfunction treatment (ED)

Cardiovascular system

Discovery research Preclinical trials Clinical trials
P-IP-II
60%

GUR-201 Critical Limb Ischemia treatment (CLI)

Musculo-skeletal system

Discovery research Preclinical trials Clinical trials
P-IP-II

Highly Effective cosmetics

Hair growth stimulation

Safety study Clinical tests Product registration
100%

REG-103 Hair growth stimulator

Anti-aging line

Safety study Clinical tests Product registration
50%

REG-201 Anti-aging skin recovery

After cosmetic surgery

Safety study Clinical tests Product registration
50%

REG-301 Skin recovery after cosmetic surgery